These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

466 related articles for article (PubMed ID: 25799991)

  • 1. Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease.
    Lee DI; Zhu G; Sasaki T; Cho GS; Hamdani N; Holewinski R; Jo SH; Danner T; Zhang M; Rainer PP; Bedja D; Kirk JA; Ranek MJ; Dostmann WR; Kwon C; Margulies KB; Van Eyk JE; Paulus WJ; Takimoto E; Kass DA
    Nature; 2015 Mar; 519(7544):472-6. PubMed ID: 25799991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PDE9A deficiency does not prevent chronic-hypoxic pulmonary hypertension in mice.
    Kolb TM; Johnston L; Damarla M; Kass DA; Hassoun PM
    Physiol Rep; 2021 Sep; 9(18):e15057. PubMed ID: 34569183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C33(S), a novel PDE9A inhibitor, protects against rat cardiac hypertrophy through upregulating cGMP signaling.
    Wang PX; Li ZM; Cai SD; Li JY; He P; Huang Y; Feng GS; Luo HB; Chen SR; Liu PQ
    Acta Pharmacol Sin; 2017 Sep; 38(9):1257-1268. PubMed ID: 28649129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy.
    Takimoto E; Champion HC; Li M; Belardi D; Ren S; Rodriguez ER; Bedja D; Gabrielson KL; Wang Y; Kass DA
    Nat Med; 2005 Feb; 11(2):214-22. PubMed ID: 15665834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. cGMP catabolism by phosphodiesterase 5A regulates cardiac adrenergic stimulation by NOS3-dependent mechanism.
    Takimoto E; Champion HC; Belardi D; Moslehi J; Mongillo M; Mergia E; Montrose DC; Isoda T; Aufiero K; Zaccolo M; Dostmann WR; Smith CJ; Kass DA
    Circ Res; 2005 Jan; 96(1):100-9. PubMed ID: 15576651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphodiesterase 9a Inhibition in Mouse Models of Diastolic Dysfunction.
    Methawasin M; Strom J; Borkowski T; Hourani Z; Runyan R; Smith JE; Granzier H
    Circ Heart Fail; 2020 May; 13(5):e006609. PubMed ID: 32418479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphodiesterase 9A regulates central cGMP and modulates responses to cholinergic and monoaminergic perturbation in vivo.
    Kleiman RJ; Chapin DS; Christoffersen C; Freeman J; Fonseca KR; Geoghegan KF; Grimwood S; Guanowsky V; Hajós M; Harms JF; Helal CJ; Hoffmann WE; Kocan GP; Majchrzak MJ; McGinnis D; McLean S; Menniti FS; Nelson F; Roof R; Schmidt AW; Seymour PA; Stephenson DT; Tingley FD; Vanase-Frawley M; Verhoest PR; Schmidt CJ
    J Pharmacol Exp Ther; 2012 May; 341(2):396-409. PubMed ID: 22328573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathological cardiac hypertrophy alters intracellular targeting of phosphodiesterase type 5 from nitric oxide synthase-3 to natriuretic peptide signaling.
    Zhang M; Takimoto E; Lee DI; Santos CX; Nakamura T; Hsu S; Jiang A; Nagayama T; Bedja D; Yuan Y; Eaton P; Shah AM; Kass DA
    Circulation; 2012 Aug; 126(8):942-51. PubMed ID: 22829024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct phosphodiesterase 5A-containing compartments allow selective regulation of cGMP-dependent signalling in human arterial smooth muscle cells.
    Wilson LS; Guo M; Umana MB; Maurice DH
    Cell Signal; 2017 Aug; 36():204-211. PubMed ID: 28506928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Marked disparity of microRNA modulation by cGMP-selective PDE5 versus PDE9 inhibitors in heart disease.
    Kokkonen-Simon KM; Saberi A; Nakamura T; Ranek MJ; Zhu G; Bedja D; Kuhn M; Halushka MK; Lee DI; Kass DA
    JCI Insight; 2018 Aug; 3(15):. PubMed ID: 30089721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nitric oxide-mediated regulation of connexin43 expression and gap junctional intercellular communication in mesangial cells.
    Yao J; Hiramatsu N; Zhu Y; Morioka T; Takeda M; Oite T; Kitamura M
    J Am Soc Nephrol; 2005 Jan; 16(1):58-67. PubMed ID: 15537869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanodomain Regulation of Cardiac Cyclic Nucleotide Signaling by Phosphodiesterases.
    Kokkonen K; Kass DA
    Annu Rev Pharmacol Toxicol; 2017 Jan; 57():455-479. PubMed ID: 27732797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CRD-733, a Novel PDE9 (Phosphodiesterase 9) Inhibitor, Reverses Pressure Overload-Induced Heart Failure.
    Richards DA; Aronovitz MJ; Liu P; Martin GL; Tam K; Pande S; Karas RH; Bloomfield DM; Mendelsohn ME; Blanton RM
    Circ Heart Fail; 2021 Jan; 14(1):e007300. PubMed ID: 33464954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of cGMP-specific phosphodiesterase 9A mRNA in the rat brain.
    Andreeva SG; Dikkes P; Epstein PM; Rosenberg PA
    J Neurosci; 2001 Nov; 21(22):9068-76. PubMed ID: 11698617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification and characterization of a new human type 9 cGMP-specific phosphodiesterase splice variant (PDE9A5). Differential tissue distribution and subcellular localization of PDE9A variants.
    Wang P; Wu P; Egan RW; Billah MM
    Gene; 2003 Sep; 314():15-27. PubMed ID: 14527714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin II increases phosphodiesterase 5A expression in vascular smooth muscle cells: a mechanism by which angiotensin II antagonizes cGMP signaling.
    Kim D; Aizawa T; Wei H; Pi X; Rybalkin SD; Berk BC; Yan C
    J Mol Cell Cardiol; 2005 Jan; 38(1):175-84. PubMed ID: 15623434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maximizing the renal cyclic 3'-5'-guanosine monophosphate system with type V phosphodiesterase inhibition and exogenous natriuretic peptide: a novel strategy to improve renal function in experimental overt heart failure.
    Chen HH; Huntley BK; Schirger JA; Cataliotti A; Burnett JC
    J Am Soc Nephrol; 2006 Oct; 17(10):2742-7. PubMed ID: 16928803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microdomain switch of cGMP-regulated phosphodiesterases leads to ANP-induced augmentation of β-adrenoceptor-stimulated contractility in early cardiac hypertrophy.
    Perera RK; Sprenger JU; Steinbrecher JH; Hübscher D; Lehnart SE; Abesser M; Schuh K; El-Armouche A; Nikolaev VO
    Circ Res; 2015 Apr; 116(8):1304-11. PubMed ID: 25688144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of phosphodiesterase isoforms 2, 5, and 9 in the regulation of NO-dependent and NO-independent cGMP production in the rat cervical spinal cord.
    de Vente J; Markerink-van Ittersum M; Vles JS
    J Chem Neuroanat; 2006 Jun; 31(4):275-303. PubMed ID: 16621445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Compartmentalization of cardiac beta-adrenergic inotropy modulation by phosphodiesterase type 5.
    Takimoto E; Belardi D; Tocchetti CG; Vahebi S; Cormaci G; Ketner EA; Moens AL; Champion HC; Kass DA
    Circulation; 2007 Apr; 115(16):2159-67. PubMed ID: 17420342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.